{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:16:59Z","timestamp":1758961019121,"version":"3.41.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s10928-015-9430-4","type":"journal-article","created":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T14:57:33Z","timestamp":1438354653000},"page":"639-657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics"],"prefix":"10.1007","volume":"42","author":[{"given":"Thierry","family":"Wendling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Dumitras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayode","family":"Ogungbenro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon","family":"Aarons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,1]]},"reference":[{"issue":"5","key":"9430_CR1","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1007\/s11095-014-1574-1","volume":"32","author":"T Wendling","year":"2015","unstructured":"Wendling T, Ogungbenro K, Pigeolet E, Dumitras S, Woessner R, Aarons L (2015) Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects. Pharm Res 32(5):1764\u20131778. doi: 10.1007\/s11095-014-1574-1","journal-title":"Pharm Res"},{"issue":"9","key":"9430_CR2","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1124\/dmd.112.050716","volume":"41","author":"M Walles","year":"2013","unstructured":"Walles M, Wolf T, Jin Y, Ritzau M, Leuthold LA, Krauser J, Gschwind HP, Carcache D, Kittelmann M, Ocwieja M, Ufer M, Woessner R, Chakraborty A, Swart P (2013) Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos 41(9):1626\u20131641. doi: 10.1124\/dmd.112.050716","journal-title":"Drug Metab Dispos"},{"key":"9430_CR3","author":"T Wendling","year":"2014","unstructured":"Wendling T, Ogungbenro K, Pigeolet E, Dumitras S, Woessner R, Aarons L (2014) Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects. Pharm Res. doi: 10.1007\/s11095-014-1574-1","journal-title":"Pharm Res"},{"issue":"9","key":"9430_CR4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1517\/17425255.4.9.1143","volume":"4","author":"AN Edginton","year":"2008","unstructured":"Edginton AN, Theil FP, Schmitt W, Willmann S (2008) Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 4(9):1143\u20131152. doi: 10.1517\/17425255.4.9.1143","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"9430_CR5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2307\/2986121","volume":"43","author":"JC Wakefield","year":"1994","unstructured":"Wakefield JC, Smith AFM (1994) Bayesian analysis of linear and non-linear population models by using the Gibbs sampler. Appl Stat 43:201\u2013221","journal-title":"Appl Stat"},{"issue":"4","key":"9430_CR6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10928-006-9011-7","volume":"33","author":"JW Yates","year":"2006","unstructured":"Yates JW (2006) Structural identifiability of physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn 33(4):421\u2013439. doi: 10.1007\/s10928-006-9011-7","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"9430_CR7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bcp.12234","volume":"79","author":"N Tsamandouras","year":"2015","unstructured":"Tsamandouras N, Rostami-Hodjegan A, Aarons L (2015) Combining the \u2018bottom up\u2019 and \u2018top down\u2019 approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol 79(1):48\u201355. doi: 10.1111\/bcp.12234","journal-title":"Br J Clin Pharmacol"},{"issue":"1\u20132","key":"9430_CR8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/03602538409015063","volume":"15","author":"LB Sheiner","year":"1984","unstructured":"Sheiner LB (1984) The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 15(1\u20132):153\u2013171. doi: 10.3109\/03602538409015063","journal-title":"Drug Metab Rev"},{"key":"9430_CR9","first-page":"61","volume":"91","author":"JC Wakefield","year":"1996","unstructured":"Wakefield JC (1996) The Bayesian analysis of population pharmacokinetic models. J Am Stat Assoc 91:61\u201376","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"9430_CR10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s002040050284","volume":"70","author":"FY Bois","year":"1996","unstructured":"Bois FY, Gelman A, Jiang J, Maszle DR, Zeise L, Alexeef G (1996) Population toxicokinetics of tetrachloroethylene. Arch Toxicol 70(6):347\u2013355","journal-title":"Arch Toxicol"},{"issue":"3","key":"9430_CR11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0300-483X(00)00356-5","volume":"157","author":"F Jonsson","year":"2001","unstructured":"Jonsson F, Johanson G (2001) Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology 157(3):177\u2013193","journal-title":"Toxicology"},{"issue":"5","key":"9430_CR12","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10928-006-9023-3","volume":"33","author":"I Gueorguieva","year":"2006","unstructured":"Gueorguieva I, Aarons L, Rowland M (2006) Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS. J Pharmacokinet Pharmacodyn 33(5):571\u2013594. doi: 10.1007\/s10928-006-9023-3","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"9430_CR13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/17425255.3.2.235","volume":"3","author":"I Nestorov","year":"2007","unstructured":"Nestorov I (2007) Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3(2):235\u2013249. doi: 10.1517\/17425255.3.2.235","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"9430_CR14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","volume":"34","author":"S Willmann","year":"2007","unstructured":"Willmann S, Hohn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W (2007) Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34(3):401\u2013431. doi: 10.1007\/s10928-007-9053-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"9430_CR15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/13543784.2014.857400","volume":"23","author":"B Gomez-Mancilla","year":"2014","unstructured":"Gomez-Mancilla B, Berry-Kravis E, Hagerman R, von Raison F, Apostol G, Ufer M, Gasparini F, Jacquemont S (2014) Development of mavoglurant and its potential for the treatment of fragile X syndrome. Expert Opin Investig Drugs 23(1):125\u2013134. doi: 10.1517\/13543784.2014.857400","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"9430_CR16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00216-012-6456-y","volume":"405","author":"A Jakab","year":"2013","unstructured":"Jakab A, Winter S, Raccuglia M, Picard F, Dumitras S, Woessner R, Mistry S, Chudasama J, Guttikar S, Kretz O (2013) Validation of an LC-MS\/MS method for the quantitative determination of mavoglurant (AFQ056) in human plasma. Anal Bioanal Chem 405(1):215\u2013223. doi: 10.1007\/s00216-012-6456-y","journal-title":"Anal Bioanal Chem"},{"issue":"3","key":"9430_CR17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0169-409X(96)00009-9","volume":"19","author":"LX Yu","year":"1996","unstructured":"Yu LX, Lipka E, Crison JR, Amidon GL (1996) Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev 19(3):359\u2013376","journal-title":"Adv Drug Deliv Rev"},{"issue":"9\u201317","key":"9430_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0378-5173(89)90069-0","volume":"51","author":"RJ Hintz","year":"1989","unstructured":"Hintz RJ, Johnson KC (1989) The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 51(9\u201317):9\u201317","journal-title":"Int J Pharm"},{"issue":"6","key":"9430_CR19","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s11095-006-0162-4","volume":"23","author":"R Takano","year":"2006","unstructured":"Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, Yamashita S (2006) Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res 23(6):1144\u20131156. doi: 10.1007\/s11095-006-0162-4","journal-title":"Pharm Res"},{"issue":"1\u20133","key":"9430_CR20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0378-4274(01)00273-9","volume":"120","author":"I Nestorov","year":"2001","unstructured":"Nestorov I (2001) Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 120(1\u20133):411\u2013420","journal-title":"Toxicol Lett"},{"issue":"6","key":"9430_CR21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/00498250600683197","volume":"36","author":"EM Howgate","year":"2006","unstructured":"Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A (2006) Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 36(6):473\u2013497. doi: 10.1080\/00498250600683197","journal-title":"Xenobiotica"},{"issue":"2","key":"9430_CR22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.2517-6161.1954.tb00159.x","volume":"16","author":"EC Fieller","year":"1954","unstructured":"Fieller EC (1954) Some problems in interval estimation. J R Stat Soc B 16(2):175\u2013185","journal-title":"J R Stat Soc B"},{"issue":"6","key":"9430_CR23","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/jps.21130","volume":"97","author":"R Jansson","year":"2008","unstructured":"Jansson R, Bredberg U, Ashton M (2008) Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicity. J Pharm Sci 97(6):2324\u20132339. doi: 10.1002\/jps.21130","journal-title":"J Pharm Sci"},{"key":"9430_CR24","volume-title":"NONMEM users guide\u2014part VIII","author":"AJ Boeckmann","year":"2013","unstructured":"Boeckmann AJ, Sheiner LB, Beal SL (2013) NONMEM users guide\u2014part VIII. ICON Development Solutions, Hanover"},{"key":"9430_CR25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1145\/838250.838251","volume":"29","author":"JRRA Martins","year":"2003","unstructured":"Martins JRRA, Sturdza P, Alonson JJ (2003) The complex-step derivative approximation. ACM Trans Math Softw 29:245\u2013262","journal-title":"ACM Trans Math Softw"},{"key":"9430_CR26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0010-2180(85)90019-7","volume":"59","author":"RA Yetter","year":"1985","unstructured":"Yetter RA, Dryer FL, Rabitz H (1985) Some interpretive aspects of elementary sensitivity gradients in combustion kinetics modeling. Combust Flame 59:107\u2013133","journal-title":"Combust Flame"},{"issue":"4","key":"9430_CR27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","volume":"7","author":"A Gelman","year":"1992","unstructured":"Gelman A, Rubin DB (1992) Inference from iterative simulation using multiple sequences. Stat Sci 7(4):457\u2013472. doi: 10.2307\/2246093","journal-title":"Stat Sci"},{"key":"9430_CR28","volume-title":"CODA manual version 0.30","author":"NG Best","year":"1995","unstructured":"Best NG, Cowles MK, Vines SK (1995) CODA manual version 0.30. MRC Biostatistics Uni, Cambridge"},{"issue":"5","key":"9430_CR29","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0016-5085(90)91150-5","volume":"99","author":"RL Oberle","year":"1990","unstructured":"Oberle RL, Chen TS, Lloyd C, Barnett JL, Owyang C, Meyer J, Amidon GL (1990) The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 99(5):1275\u20131282","journal-title":"Gastroenterology"},{"issue":"2","key":"9430_CR30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0939-6411(97)00088-X","volume":"45","author":"LX Yu","year":"1998","unstructured":"Yu LX, Amidon GL (1998) Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm 45(2):199\u2013203","journal-title":"Eur J Pharm Biopharm"},{"key":"9430_CR31","author":"N Tsamandouras","year":"2015","unstructured":"Tsamandouras N, Wendling T, Rostami-Hodjegan A, Galetin A, Aarons L (2015) Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations. J Pharmacokinet Pharmacodyn. doi: 10.1007\/s10928-015-9418-0","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"10","key":"9430_CR32","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2005.02683.x","volume":"22","author":"C Schiller","year":"2005","unstructured":"Schiller C, Frohlich CP, Giessmann T, Siegmund W, Monnikes H, Hosten N, Weitschies W (2005) Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther 22(10):971\u2013979. doi: 10.1111\/j.1365-2036.2005.02683.x","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"9430_CR33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/mp4003392","volume":"11","author":"H Lennernas","year":"2014","unstructured":"Lennernas H (2014) Human in vivo regional intestinal permeability: importance for pharmaceutical drug development. Mol Pharm 11(1):12\u201323. doi: 10.1021\/mp4003392","journal-title":"Mol Pharm"},{"issue":"1\u20132","key":"9430_CR34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0146-6453(03)00011-3","volume":"32","author":"J Valentin","year":"2002","unstructured":"Valentin J (2002) Guide for the practical application of the ICRP Human Respiratory Tract Model. A report of ICRP supporting guidance 3: approved by ICRP committee 2 in October 2000. Ann ICRP 32(1\u20132):13\u2013306","journal-title":"Ann ICRP"},{"issue":"1","key":"9430_CR35","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1006\/jsre.2000.5862","volume":"93","author":"PJ Matheson","year":"2000","unstructured":"Matheson PJ, Wilson MA, Garrison RN (2000) Regulation of intestinal blood flow. J Surg Res 93(1):182\u2013196. doi: 10.1006\/jsre.2000.5862","journal-title":"J Surg Res"},{"issue":"3","key":"9430_CR36","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","volume":"283","author":"MF Paine","year":"1997","unstructured":"Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharm Exp Ther 283(3):1552\u20131562","journal-title":"J Pharm Exp Ther"},{"issue":"10","key":"9430_CR37","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1023\/A:1020483911355","volume":"19","author":"D Sun","year":"2002","unstructured":"Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, Amidon GL (2002) Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 19(10):1400\u20131416","journal-title":"Pharm Res"},{"key":"9430_CR38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejps.2014.02.010","volume":"57","author":"E Sjogren","year":"2014","unstructured":"Sjogren E, Abrahamsson B, Augustijns P, Becker D, Bolger MB, Brewster M, Brouwers J, Flanagan T, Harwood M, Heinen C, Holm R, Juretschke HP, Kubbinga M, Lindahl A, Lukacova V, Munster U, Neuhoff S, Nguyen MA, Peer A, Reppas C, Hodjegan AR, Tannergren C, Weitschies W, Wilson C, Zane P, Lennernas H, Langguth P (2014) In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation\/API\/excipient characterization including food effects. Eur J Pharm Sci 57:99\u2013151. doi: 10.1016\/j.ejps.2014.02.010","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"9430_CR39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0091270008331196","volume":"49","author":"P Zhao","year":"2009","unstructured":"Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang SM (2009) Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 49(3):351\u2013359. doi: 10.1177\/0091270008331196","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"9430_CR40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/0091270004270642","volume":"45","author":"RL Walsky","year":"2005","unstructured":"Walsky RL, Gaman EA, Obach RS (2005) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45(1):68\u201378. doi: 10.1177\/0091270004270642","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"9430_CR41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/dmd.32.1.105","volume":"32","author":"DM Stresser","year":"2004","unstructured":"Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, Patten CJ, Dehal SS, Crespi CL (2004) Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 32(1):105\u2013112. doi: 10.1124\/dmd.32.1.105","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"9430_CR42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejps.2009.12.002","volume":"39","author":"K Rowland Yeo","year":"2010","unstructured":"Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug\u2013drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut\u2014the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39(5):298\u2013309. doi: 10.1016\/j.ejps.2009.12.002","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"9430_CR43","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45(9):931\u2013956. doi: 10.2165\/00003088-200645090-00005","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"9430_CR44","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","volume":"45","author":"AN Edginton","year":"2006","unstructured":"Edginton AN, Schmitt W, Willmann S (2006) Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 45(10):1013\u20131034. doi: 10.2165\/00003088-200645100-00005","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"9430_CR45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2165\/00003088-200645070-00004","volume":"45","author":"AN Edginton","year":"2006","unstructured":"Edginton AN, Schmitt W, Voith B, Willmann S (2006) A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet 45(7):683\u2013704. doi: 10.2165\/00003088-200645070-00004","journal-title":"Clin Pharmacokinet"},{"key":"9430_CR46","unstructured":"ICRP (1975) Report of the task group on reference man. ICRP Publication 23, Pergamon Press, Oxford"},{"issue":"6","key":"9430_CR47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10928-009-9141-9","volume":"36","author":"A Dokoumetzidis","year":"2009","unstructured":"Dokoumetzidis A, Aarons L (2009) A method for robust model order reduction in pharmacokinetics. J Pharmacokinet Pharmacodyn 36(6):613\u2013628. doi: 10.1007\/s10928-009-9141-9","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"9430_CR48","doi-asserted-by":"crossref","first-page":"e44064","DOI":"10.1371\/journal.pone.0044064","volume":"7","author":"AL Jorgensen","year":"2012","unstructured":"Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR (2012) Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One 7(8):e44064. doi: 10.1371\/journal.pone.0044064","journal-title":"PLoS One"},{"issue":"7","key":"9430_CR49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1021\/js980236p","volume":"88","author":"J Wang","year":"1999","unstructured":"Wang J, Flanagan DR (1999) General solution for diffusion-controlled dissolution of spherical particles. 1. Theory. J Pharm Sci 88(7):731\u2013738. doi: 10.1021\/js980236p","journal-title":"J Pharm Sci"},{"issue":"2","key":"9430_CR50","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jps.10039","volume":"91","author":"J Wang","year":"2002","unstructured":"Wang J, Flanagan DR (2002) General solution for diffusion-controlled dissolution of spherical particles. 2. Evaluation of experimental data. J Pharm Sci 91(2):534\u2013542","journal-title":"J Pharm Sci"},{"issue":"7","key":"9430_CR51","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.23616","volume":"26","author":"D Berg","year":"2011","unstructured":"Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26(7):1243\u20131250. doi: 10.1002\/mds.23616","journal-title":"Mov Disord"},{"issue":"13","key":"9430_CR52","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/mds.25561","volume":"28","author":"F Stocchi","year":"2013","unstructured":"Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C (2013) AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 28(13):1838\u20131846. doi: 10.1002\/mds.25561","journal-title":"Mov Disord"},{"issue":"4","key":"9430_CR53","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","volume":"13","author":"RP Brown","year":"1997","unstructured":"Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407\u2013484","journal-title":"Toxicol Ind Health"},{"issue":"7","key":"9430_CR54","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","volume":"8","author":"J Yang","year":"2007","unstructured":"Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8(7):676\u2013684","journal-title":"Curr Drug Metab"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-015-9430-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-015-9430-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-015-9430-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T20:50:26Z","timestamp":1748551826000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-015-9430-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,1]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["9430"],"URL":"https:\/\/doi.org\/10.1007\/s10928-015-9430-4","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"type":"print","value":"1567-567X"},{"type":"electronic","value":"1573-8744"}],"subject":[],"published":{"date-parts":[[2015,8,1]]}}}